Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,120,000 shares, a growth of 21.8% from the March 31st total of 919,900 shares. Currently, 16.3% of the company's stock are sold short. Based on an average daily trading volume, of 1,630,000 shares, the days-to-cover ratio is currently 0.7 days.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP traded up $1.96 during midday trading on Friday, reaching $20.00. The stock had a trading volume of 844,094 shares, compared to its average volume of 788,432. The stock has a market capitalization of $128.70 million, a P/E ratio of 0.00 and a beta of 1.50. Tonix Pharmaceuticals has a 1-year low of $6.76 and a 1-year high of $672.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm's fifty day simple moving average is $16.88 and its 200-day simple moving average is $20.64.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing analysts' consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. On average, equities research analysts forecast that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Analyst Ratings Changes

TNXP has been the subject of a number of analyst reports. Noble Financial reaffirmed an "outperform" rating and issued a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th. StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a "sell" rating on the stock.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC bought a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $40,000. Two Sigma Investments LP bought a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at about $66,000. PFG Investments LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter worth about $72,000. Northern Trust Corp bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, Rhumbline Advisers acquired a new position in Tonix Pharmaceuticals in the 1st quarter valued at approximately $244,000. Institutional investors and hedge funds own 82.26% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.